SM1702

SM1702 is a highly selective, small molecule antagonist of the P2X3 receptor (P2RX3), currently in preclinical development by Shanghai SIMR Biotechnology (SIMR). The P2X3 receptor is a trimeric ligand-gated ion channel activated by extracellular ATP, primarily located on small-diameter sensory neurons (C-fibers). Its overactivation is a key driver in the peripheral sensitization of the cough reflex and various chronic pain states. SM1702 is being developed for the treatment of refractory or unexplained chronic cough and neuropathic pain. By specifically targeting the P2X3 homomeric receptor over the P2X2/3 heteromeric receptor, SM1702 aims to provide therapeutic efficacy while minimizing the taste-related side effects (dysgeusia) commonly observed with first-generation P2X3 inhibitors.